|
I've been avoiding the day-to-day market as the biotech bear continues its rounds...I did notice the mention that PFE might not renew its subscription to the INCY database and the consternation that rumor(or fact) appeared to play with the valuation...I went over to the INCY site..In '97 the company signed-on/or expanded relationships with: Rhone-Poulenc, Monsanto, Organon, Glaxo, Pharmacia, Bristol-Myers, Smithkline Beecham, Genentech, etc. This excludes the "hardware" deals with the high-throughput people, the diagnostic collaborations, etc...While the PFE rumor may play-out, it appears that INCY is not a one-trick pony... |
